**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52255

**Manuscript Type:** ORIGINAL ARTICLE

*Basic Study*

**Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice**

Tashita C *et al*. Role of kynurenine in TNBS-induced colitis

Chieko Tashita, Masato Hoshi, Akihiro Hirata, Kentaro Nakamoto, Tatsuya Ando, Takayuki Hattori, Yasuko Yamamoto, Hiroyuki Tezuka, Hiroyuki Tomita, Akira Hara, Kuniaki Saito

**Chieko Tashita, Kentaro Nakamoto, Tatsuya Ando, Yasuko Yamamoto, Kuniaki Saito,** Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake 470-1192, Japan

**Masato Hoshi,** Department of Biochemical and Analytical Science, Fujita Health University Graduate School of Health Sciences, Toyoake 470-1192, Japan

**Hiroyuki Tezuka, Tatsuya Ando,** Department of Cellular Function Analysis, Research Promotion and Support Headquarters, Fujita Health University Graduate School of Health Sciences, Toyoake 470-1192, Japan

**Akihiro Hirata,** Division of Animal Experiment, Life Science Research Center, Gifu University, Gifu 501-1193, Japan

**Takayuki Hattori,** Faculty of Medical Technology, Gifu University of Medical Science, Gifu 501-3892, Japan

**Hiroyuki Tomita, Akira Hara,** Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 501-1193, Japan

**Author contributions:** Hoshi M, Hara A, and Saito K planned the studies; Tashita C, Hoshi M, Hirata A, Tezuka H, Hattori T, Yamamoto Y, and Tomita H performed the experiments; Tashita C and Hoshi M had responsibility for all data integrity and data analysis; Tashita C, Hoshi M, Hirata A, Tezuka H, Nakamoto K, Ando T, Hattori T, Yamamoto Y, Tomita H, Hara A, and Saito K discussed the results; Tashita C, Hoshi M, and Tezuka H wrote the manuscript; Hara A and Saito K conducted the research; Saito K had primary responsibility for the final content; all authors reviewed and approved the manuscript.

**Supported by** Grants-in-Aids for Young Scientists (B) from the Japan Society for the Promotion of Science, No. 17K15785; and Fujita Health University Grant (2018).

**Corresponding author: Masato Hoshi, PhD, Assistant Professor,** Department of Biochemical and Analytical Science, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan. mhoshi@fujita-hu.ac.jp

**Received:** November 5, 2019

**Revised:** January 6, 2020

**Accepted:** February 21, 2020

**Published online:**

**Abstract**

BACKGROUND

Inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis, is characterized by chronic intestinal inflammation leading to intestinal mucosal damage. Inflammatory bowel disease causes dysregulation of mucosal T cell responses, especially the responses of CD4+ T cells. Previously, we demonstrated that indoleamine-2,3-dioxygenase plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate (TNBS)-induced colitis. Although indoleamine-2,3-dioxygenase exerts immunosuppressive effects by altering the local concentration of tryptophan (Trp) and immunomodulatory Trp metabolites, the specific changes in immune regulation during colitis caused by Trp metabolites and its related enzymes remain unclear.

AIM

To investigate role of kynurenine 3-monooxygenase (KMO) in TNBS-induced colitis and involvement of Trp metabolites in maintenance of intestinal homeostasis.

METHODS

Colitis was induced in eight-week-old male KMO+/+ or KMO−/− mice of C57BL/6N background using TNBS. Three days later, the colon was used for hematoxylin-eosin staining for histological grading, immunohistochemical or immunofluorescence staining for KMO, cytokines, and immune cells. Inflammatory and anti-inflammatory cytokines were measured using quantitative RT-PCR, and kynurenine (Kyn) pathway metabolites were measured by high-performance liquid chromatography. The cell proportions of colonic lamina propria cell and mesenteric lymph nodes were analyzed by flow cytometry.

RESULTS

KMO expression levels in the colonic mononuclear phagocytes, including dendritic cells and macrophages increased upon TNBS induction. Notably, KMO deficiency reduced TNBS-induced colitis, resulting in an increased frequency of Foxp3+ regulatory T cells and increased mRNA and protein levels of anti-inflammatory cytokines, including transforming growth factor-β and interleukin-10.

CONCLUSION

Absence of KMO reduced TNBS-induced colitis *via* generation of Foxp3+ regulatory T cells by producing Kyn. Thus, Kyn may play a therapeutic role in colon protection during colitis.

**Key words:** Kynurenine 3-monooxygenase; Kynurenine; Regulatory T cell; Inflammatory bowie diseases

Tashita C, Hoshi M, Hirata A, Nakamoto K, Ando T, Hattori H, Yamamoto Y, Tezuka H, Tomita H, Hara A, Saito K. Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. *World J Gastroenterol* 2020; In press

**Core tip:** The role of kynurenine 3-monooxygenase (KMO) in immune regulation was examined in *KMO* gene deficient mice suffering from 2,4,6-trinitrobenzene sulfate-induced colitis. We demonstrated that the expression of transforming growth factor-β and interleukin-10 in the colon of these mice was upregulated by KMO inhibition and kynurenine administration, resulting in increased incidence of regulatory T cells in the inflammatory site, where they suppress progression to colitis. Thus, administration of kynurenine plays a critical role in host protection during 2,4,6-trinitrobenzene sulfate-induced colitis.

**INTRODUCTION**

Inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by chronic intestinal inflammation leading to damage of the intestinal mucosa, which may persist for a long term. Consequently, therapy corresponding to stage and the lifestyle of the patient is important. Recent studies have suggested that IBD causes dysregulation of mucosal T cell responses, especially those of CD4+ T cells[1], leading to intestinal inflammation and barrier destruction[2,3]. Further, CD4+ T helper (Th) cells, including Th1 and Th2, and regulatory T (Treg) cells regulate the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ and anti-inflammatory cytokines, such as transforming growth factor (TGF)-β and interleukin (IL)-10 in the intestines[4]. Thus, it is known that dysregulation of these cytokines is an important characteristic of IBD. For example, Crohn’s disease and ulcerative colitis are associated with inflammatory Th1- and Th2-responses, respectively[5]. The regulatory function of Treg cells on colonic inflammation is mainly exerted by the production of anti-inflammatory cytokines, such as IL-10 and TGF-β[6-8], leading to the suppression of inflammatory Th1- and Th2-responses[9]. Importantly, the deletion of Treg cells leads to the onset of chronic T cell-mediated intestinal inflammation and worsens acute intestinal inflammation[10], suggesting that Treg cells may be beneficial in the treatment of colonic inflammation[11]. Moreover, a recent study suggested that Th17 cells play an important role during IBD[12] by producing pro-inflammatory cytokines such as IFN-γ and IL-17. Therefore, the immune responses in the intestine are important because the balance between congenital and secondary responses, and negative regulation, and impairment of such balance by genetic or environmental factors leads to inflammatory disorders such as the IBD[5,13-15]. However, the roles of the pro-inflammatory processes and of immune regulation during colitis still remain unclear.

We recently demonstrated that the activity of indoleamine-2,3-dioxygenase (IDO), which catalyzes the rate-controlling step in the kynurenine pathway (KP), plays an immunosuppressive role during colitis[16]. IDO exerts immunosuppressive effects by reducing the local concentration of tryptophan (Trp) and increasing the production of immunomodulatory Trp metabolites that have a variety of effects on immune cells. For example, the Trp metabolites suppress proliferation and promote apoptosis of T cells[17,18], and induce the differentiation of naive T cells into Treg cells. In addition, recent studies have shown that increase in IDO concentrations in some tissues inhibits migration of effector T cells[19]. Although regulation of KP metabolism has attracted considerable attention as a novel target for the development of colitis therapeutics, the immunosuppressive effects of Trp metabolites and the KP enzymes associated with them are not fully understood.

Kynurenine-3-monooxygenase (KMO) is a key enzyme in KP, that biosynthesizes 3-hydroxykynurenine (3-HK) from kynurenine (Kyn) with the aid of nicotinamide adenine dinucleotide phosphate (NADPH)[20]. KMO is predominantly localized in the mitochondria and exhibits the highest activity in the liver, kidney, and immune cells, especially macrophages[21]. The transcriptional expression of KMO is induced by IFN-γ and is inhibited by IL-4[22]. Recently, we demonstrated that *KMO* gene deficiency in mice leads to high levels of Kyn and low levels of 3-HK in serum and various tissues[23]. Kyn is involved in arterial relaxation[24] and generation of Treg[25]. Based on these findings, we hypothesized that increased levels of Kyn, caused by regulating KMO, may contribute to the induction of intestinal T cells and other immune cells during colitis.

**MATERIALS AND METHODS**

***Animals***

Eight-week-old male mice were used for this study. *KMO* gene deficient (KMO−/−) mice on a C 57BL/6N background were obtained from the Knockout Mouse Project (KOMP) repository. Homozygous KMO−/− and KMO+/+ mice were generated by intercrossing heterozygous mice and genotyped using standard PCR-based genotyping of genomic DNA extracted from tail snippets. The following primer sequences were used for PCR genotyping: *KMO* gene sense: 5′-TTCTGACCCCATCTGTGTCTGTTCC-3′, antisense: 5′-ATCAGAGCTCCCTAAATATGGTGGC-3′; and *KMO* gene deficiency sense: 5′-AACTTCGACCCTTTCCCAC-3′, antisense: 5′-GACCACCTCATCAGAGCAG-5′. The mice were housed in a specific pathogen-free environment in our animal facility. All experiments were performed in accordance with Guidelines for Animal Care of the Fujita Health University. Mice were acclimatized to controlled conditions (12 h/12 h light/dark cycle, 50% humidity, 23 °C ± 2 °C, *ad libitum* access to food and water) for two weeks prior to experimentation. The protocol for all animal experiments was approved by the Animal Experimentation Committee of Fujita Health University Graduate School of Medicine. Procedures involving mice and their care conformed to international guidelines, as described in Principles of Laboratory Animal Care (National Institutes of Health publication 85-23, revised 1985).

***Induction of acute colitis***

Eight-week-old KMO−/− or KMO+/+ mice were allotted to four groups: TNBS-treated (KMO−/− mice; at least *n* = 4, KMO+/+ mice; at least *n* = 4) and ethanol-treated (vehicle, TNBS solvent control) (KMO−/− mice; at least *n* = 4, KMO+/+ mice; at least *n* = 5). Treatment of the mice with TNBS (obtained from Sigma-Aldrich, St. Louis, MO) and vehicle was performed as described previously[26]. Mice were placed under anesthesia, and intrarectally injected with either 100 μl TNBS (2.5% TNBS in 50% ethanol) or 50% ethanol. All surviving mice were sacrificed three days after the TNBS treatment. Any steps taken to minimize the effects of subjective bias when allocating mice to treatment.

***Sample preparation***

The colon was opened longitudinally and cut in half in the direction of the long axis. One half was fixed in phosphate-buffered 10% formalin for 24 h at room temperature. The tissue sample was then processed for histological and immunohistological analyses as described later. The second half of the colon was used for quantitative real-time RT-PCR analysis, enzymatic assays, or analysis of Trp metabolites.

***Histological analysis***

Three micrometer-thick sections of the colon were used for hematoxylin-eosin staining for histological grading. The colon tissue was divided into three separate sections. The histological grades were determined for each section and the sum of the grades was reported as the inflammation score for each mouse. Histological grading of colitis was determined on a scale of 0 to 5 as described previously[16]. Grade 0: No obvious inflammation; Grade 1: Mild inflammatory cell infiltration, no structural changes observed; Grade 2: Moderate inflammatory cell infiltration, crypt elongation, bowel wall thickening that does not extend beyond the mucosal layer, no evidence of ulceration; Grade 3: Severe inflammation cell infiltration, thickening of bowel wall, high vascular density, crypt elongation with distortion, transmural bowel wall thickening with ulceration that extends beyond the mucosal layer; Grade 4: Complete loss of mucosal architecture (crypts) with ulceration and loss of mucosal vasculature; Grade 5: Coagulative necrosis of the mucosal layer. Illustrative images of the colon at each grade are shown in Supplementary Figure 1.

***Measurement of KP metabolites***

For Trp, Kyn, 3-HK, kynurenic acid (KA), anthranilic acid (AA), and 3-hydroxyanthranilic acid (3-HAA) measurement, colon tissues were homogenized. The homogenate samples were centrifuged at 7000 × g at 4 °C for 10 min. Fifty microliters of the supernatant was subjected to high-performance liquid chromatography (HPLC) analysis. Trp, Kyn, KA, and AA were isocratically eluted from a reverse phase column [TSKgel ODS-100V, 3 μm, 4.6 mm (ID) × 150 nm (L)] (Tosoh, Tokyo, Japan) using a mobile phase containing 10 mmol/L sodium acetate and 1% acetonitrile (adjusted pH to 4.5 with acetic acid) at a flow rate of 0.9 ml/min. Trp and Kyn were detected using an ultraviolet and visible spectrophotometric apparatus (SPD-20A, Shimadzu, Kyoto, Japan) (UV wavelength for Trp: 280 nm, UV wavelength for Kyn: 365 nm). AA, KA, and 3-HAA were detected by a fluorescence detector (RF-20Axs) (Shimadzu) under the following conditions: the excitation wavelength 320 nm and emission wavelength 420 nm for AA and 3-HAA, the excitation wavelength 334 nm and emission wavelength 380 nm for KA. Twenty microliters of the supernatant was injected into a 3 μm HPLC column (HR-80; 80 mm × 4.6 mm) (ESA, Chelmsford, MA), using a mobile phase consisting of 1.5% acetonitrile, 0.9% trimethylamine, 0.59% phosphoric acid, 0.27 mmol/L EDTA, and 8.9 mmol/L sodium heptane sulfonic acid, at a flow rate of 0.5 mL/min. 3-HK was detected electrochemically using an ECD 300 detector (oxidation potential: +0.05 V) (Eicom, Kyoto, Japan) as described previously[27].

***Immunohistochemical analysis***

Three micrometer-thick sections of the colon were used for immunohistochemical staining for KMO, CD4, and Foxp3. The primary antibodies used were rabbit anti-KMO antibody (ab83929, Abcam, Abcam Cambridge, United Kingdom), and rabbit anti-CD4 antibody (ab183685, Abcam), and rabbit anti-Foxp3 antibody (ab545011, Abcam). After deparaffinization and rehydration, sections were heated at 121 °C for 20 min in Histofine antigen retrieval solution (pH 9.0) (NICHIREI BIOSCIENCE INC., Tokyo, Japan) for CD4 or 0.1 mol/L sodium citrate buffer (pH 6.0) for KMO and Foxp3. The sections were soaked in 3% hydrogen peroxide in methanol for 30 min to eliminate endogenous peroxidase activity. After nonspecific binding was blocked with 1% BSA, the sections were incubated with primary antibodies overnight at 4°C. Positive and negative controls (no primary antibody) were included for each antibody (Supplementary Figure 2). Secondary antibody, conjugated with a peroxidase polymer (ImmPRESS Reagent anti-rabbit IgG Vector Laboratories, Burlingame, CA) was added for 30 min at room temperature, followed by the addition of the substrate 3,3`-diaminobenzidine tetrahydrochloride (DAB; Dako, Santa Clara, CA). The sections were then counterstained with hematoxylin. For immunofluorescence analysis, the frozen colon sections were used for immunohistochemical staining for KMO, F4/80, CD19, CD11c, Foxp3, TGF-β, and IL-10. The nonspecific binding was blocked with 1% BSA in PBS or M.O.M mouse Ig blocking reagent for TGF-β staining (M.O.M kit, Vector Laboratories), and the sections were subsequently incubated with rabbit anti-KMO antibody (ab83929, Abcam) and rat monoclonal anti-F4/80 antibody (ab16911, Abcam), rabbit anti-Foxp3 antibody (ab545011, Abcam), mouse monoclonal anti-TGF-β antibody (NBP2-45137, Novus Biological, Littleton, CO), rat monoclonal anti-IL-10 antibody (MBS246583, MyBioSource, San Diego, CA), rat monoclonal anti-CD19 antibody (14-0194-82, Thermo Fisher Scientific, Tokyo, Japan) and hamster monoclonal anti-CD11c antibody (70-0114, TONBO Biosciences, San Diego, CA) in 2% BSA in PBS overnight at 4 °C. Negative controls (without primary antibodies) were included for each antibody (Supplementary Figure 3). After the incubation with primary antibodies, the sections were rinsed with PBS, and incubated with secondary antibodies for 30 min at room temperature. The secondary antibodies used were Alexa Fluor® 488-conjugated donkey anti-rabbit IgG (H+L) antibody (NL004, R&D Systems, Minneapolis, MN), donkey anti-mouse IgG (H+L) antibody (NL009, R&D Systems) and goat anti-rat IgG (H+L) antibody (ab150157, Abcam), FITC-conjugated anti-hamster IgG (H+L) antibody (31587, Thermo Fisher Scientific) and nuclei were stained with 4′,6-diamidino-2-phenylindole (Dojindo, Tokyo, Japan). Immunostained slides were observed under fluorescence microscope BX51 equipped with a DP74 digital camera (Olympus, Tokyo, Japan).

***Cell preparation and Flow cytometry***

To prepare colonic lamina propria (LP) cells, the colon was opened longitudinally and cut into 2-3 fragments. The fragments were stirred to remove epithelial cells in 3 mmol/L ethylenediaminetetraacetic acid (EDTA) solution (220 r/min, 30 min, 37°C) and then digested in 100 U/ml of type Ⅰ collagenases (FUJIFILM Wako, Osaka, Japan) (220 r/min, 45 min, 37 °C). Digested fragments were passed through a 70-μm cell strainer and then applied to a discontinuous Percoll density gradient (GE Healthcare, Illinois, CHI) of 44% Percoll and 60%. Cells at the interface were collected and used as colonic LP cells. Mesenteric lymph nodes (MLN) were dissociated into single-cells and then passed through a 70-μm cell strainer and used as MLN cells. Cells were stained with fluorochrome-conjugated monoclonal antibodies against the following cell-surface makers: FITC anti-mouse CD4 (GK1.5, BioLegend, San Diego, CA), PE anti-mouse CD103 (2E7, BioLegend), APC anti-mouse CD11c (N418, BioLegend) and FITC anti-mouse CD45.2 (104, BioLegend). For intracellular Foxp3 staining, cells were fixed and permeabilized with Foxp3 Fix/Perm solution (BioLegend). Cells were then stained with biotin-conjugated anti-mouse Foxp3 antibody (FJK-16s, BioLegend) followed by streptavidin-conjugated APC (405207, BioLegend). The cells were analyzed on FACS Calibur in conjunction with FlowJo software (BD Bioscience, Tokyo, Japan).

***RNA extraction and quantitative PCR***

Total RNA was extracted from the colon tissue using Isogen II (NIPPON GENE, Tokyo, Japan). cDNA was synthesized using High-capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster city, CA) for RT-PCR according to the manufacturer’s instructions. The following PCR primers were used: KMO, sense, 5′-GTTATTGGCGGTGGTTTGGTTG-3′, and antisense, 5′-GGGCCAAGTTAATGCTCCTTC-3′; 18S rRNA, sense 5′-GGATTGACAGATTGATAGC-3′, and antisense, 5′-TATCGGAATTAACCAGACAA-3′; IFN-γ, sense, 5′-AAGTTTGAGGTCAACAAC-3′, and anti-sense, 5′-GTGCTGGCAGAATTATTC-3′; TGF-β, sense, 5′-ACAATTCCTGGCGTTACCTTG-3′, and anti-sense, 5′-CGTGGAGTTTGTTATCTTTGCTG-3′; IL-10, sense, 5′-TGCACTACCAAAGCCACAAG-3′, and anti-sense, 5′-TAAGAGCAGGCAGCATAGCAG-3′; and TNF-α, sense, 5′-TCATGCACCACCATCAAG-3′, and antisense, 5′-CAGAACTCAGGAATGGACAT-3′.

KMO, TGF-β, IL-10, IFN-γ, TNF-α and 18S rRNA were quantified by using SYBR Green Supermix (Bio Rad, Hercules, CA) on Step One Real Time PCR System (Applied Biosystems). The expression of each gene was normalized to the expression of 18S rRNA using the standard curve method.

***Administration of Kyn***

Kyn was administered as described previously[28]. Briefly, mice were intraperitoneally injected with L-Kyn (*n* = 5, 100 mg/kg, twice per day, Sigma-Aldrich, Tokyo, Japan), KA (*n* = 5), AA (*n* = 5), 3-HAA (*n* = 3), and 3-HK (*n* = 3, 10 mg/kg, twice per day, respectively, Sigma-Aldrich) at 12 h after TNBS injection and were humanely sacrificed on day 3.

***Statistical analysis***

Results are presented as the mean ± SE. For analyzing multiple groups, two-way ANOVA was used followed by Tukey multiple comparisons test, except for KMO expression, which was performed using one-way ANOVA followed by Tukey multiple comparison test, and Kyn-treated mice or vehicle mice were analyzed by Student’s *t*-test. All comparison and observations were performed using GraphPad Prism7 (GraphPad Software Inc., San Diego, CA). *P* < 0.05 was considered significant.

**RESULTS**

***Absence of KMO suppresses TNBS-induced colitis in mice***

We examined the effects of the KMO−/− genotypeto investigate the role of KMO during colitis. There was no difference in length, weight, or histological appearance of the colon and body weight between untreated KMO+/+ mice and untreated KMO−/− mice (data not shown). The histological grades of colonic inflammation were consistently higher in TNBS-treated than in vehicle-treated KMO+/+ mice (*P* < 0.01), and the histological grades of colonic inflammation and the ratio of colon to body weight (Supplementary Figure 4) in TNBS-treated KMO−/− mice (*P* < 0.05) were significantly lower compared to those in TNBS-treated KMO+/+ mice (Figure 1A and B). KMO−/− mice suffering from TNBS-induced colitis showed relatively mild inflammation and occasionally developed focal ulceration. In contrast, in KMO+/+ mice, colitis was frequently associated with pathological changes in the colonic mucosa, including extensive ulceration, crypt loss, and coagulative necrosis (Figure 1B). We next assessed the expression of KMO in the colon by quantitative PCR and immunohistochemical staining. In KMO+/+ mice, the number of KMO+ cells and KMO mRNA levels were significantly higher in TNBS-treated groups (*P* < 0.05) than in vehicle-treated groups (Figure 1C-E). Interestingly, KMO was expressed in F4/80+ cells and CD11c+ cells, but not in CD19+ cells, as observed by immunofluorescence analysis (Figure 1F, Supplementary Figure 5). These observations indicate that TNBS-induced KMO+ mononuclear phagocytes (MPs), including possibly dendritic cells and macrophages, were involved in the pathological progression of colitis.

***KMO gene deficiency markedly changes the levels of KP metabolites in the colon***

Because KMO deficiency has been associated with significantly reduced inflammation, we next investigated the effects of KP metabolites in the TNBS-induced colitis model. The levels of Kyn and KA in the colonic tissues were significantly higher in TNBS-treated KMO−/− mice (Kyn: *P* < 0.05; KA: *P <* 0.01) than those in KMO−/− vehicle mice. In contrast, the levels of Kyn, AA, and KA in TNBS-treated (Kyn, KA: *P* < 0.01; AA: *P* < 0.05) and vehicle-treated KMO−/− mice (Kyn, KA: *P* < 0.01; AA: *P* < 0.05) were significantly higher compared to those in TNBS-treated and vehicle-treated KMO+/+ mice (Figure 2). As expected, the levels of 3-HK and 3-HAA remained low in TNBS-treated KMO−/− mice. The levels of Trp were unaffected in all mice tested regardless of presence or absence of KMO (Figure 2). These results suggest that increased levels of KP metabolites, excluding 3-HK and 3-HAA, resulting from KMO deficiency might also contribute to the regulation of colonic inflammation.

***Increase in Kyn levels in the colon of KMO−/− mice promotes Foxp3+ Treg cell accumulation***

Treg cells prevent the induction and progression of colitis[6-8]. Therefore, we quantified the proportion of Foxp3+ Treg cells in the inflamed colon by immunohistochemical staining and flow cytometry. To this end, we evaluated the Foxp3+ Treg cells on serial sections (Figure 3A). During colitis, the frequency of colonic Treg cells was significantly higher in KMO−/− mice (*P* < 0.05) than in KMO+/+ mice (Figure 3B and C). Consistent with these results, the frequency of CD103+ DCs in the MLN was higher in KMO−/− mice (*P* < 0.05) than in KMO+/+ mice under inflammatory conditions (Figure 3D and E). These results suggest that KMO−/− mice showed enhanced induction or accumulation of Foxp3+ Treg cells in the inflamed colon.

***Upregulation of anti-inflammatory cytokines in the colon of KMO−/− mice***

Anti-inflammatory cytokines, which are largely produced by Treg cells, regulate intestinal inflammation including colitis. To examine whether reduced inflammation in KMO−/− mice is due to enhanced productionof anti-inflammatory cytokines, we first examined the levels of mRNA expression of TGF-β and IL-10 in the colonic tissues. The levels of TGF-β and IL-10 mRNA in the colon of TNBS-treated KMO−/− mice (*P* < 0.05) were significantly higher than those of TNBS-treated KMO+/+ mice (Figure 4A). In contrast, the levels of inflammatory cytokines TNF-α and IFN-γ mRNA tended to reduce in the colon of TNBS-treated KMO−/− mice compared to the colon of TNBS-treated KMO+/+ mice (Figure 4A). We next performed immunofluorescence staining to determine the source of TGF-β and IL-10. In the colonic lamina propria (LP) of vehicle or TNBS-treated KMO+/+ mice, the expression of TGF-β and IL-10 was largely observed in Foxp3+ Treg cells, but not in colonic epithelium (Figure 4B). Furthermore, the ratio of TGF-β+ /Foxp3+ cells and IL-10+/ Foxp3+ cells in the isolated lymphoid follicles (ILF) in the colon was significantly higher in TNBS-treated KMO−/− mice (*P <* 0.01) than in TNBS-treated KMO+/+ mice (Figure 4D). However, the ratio of TGF-β+/Foxp3+ cells and IL-10+/ Foxp3+ cells in the colonic LP and mesenteric lymph nodes (MLN) was not significantly altered between these mice (data not shown). These results suggest that Foxp3+ Treg cells accumulate in the colonic ILF and suppress colitis through enhanced Kyn-dependent production of TGF-β and IL-10.

***Treatment with Kyn improves TNBS-induced colitis***

To evaluate the effects of Trp metabolites in TNBS-induced colitis, we administrated Kyn, KA, or AA to TNBS-treated KMO+/+ mice and 3-HK or 3HAA to KMO−/− mice. The histological grades of colonic inflammation and the ratio of colon to body weight in Kyn-treated mice (inflammation score: *P* = 0.05; colon/B.W.: *P* < 0.05) were reduced compared to those in KA, AA, and PBS-treated KMO+/+ mice (Figure 5A left and Supplementary Figure 6). Moreover, these indicators for colonic inflammation in 3-HK-treated KMO−/− mice were increased compared to those in 3HAA- or PBS-treated mice (*P* < 0.05) (Figure 5A right). Kyn-treated KMO+/+ mice had relatively mild inflammation and occasionally developed focal ulceration. In contrast, KA, AA, and PBS-treated KMO+/+ mice and 3-HK-treated KMO−/− mice exhibited severe inflammation with pathogenic changes in the colonic mucosal architecture including extensive ulceration and coagulative necrosis (Figure 5B and Supplementary Figure 7). Furthermore, the ratio of Foxp3+/CD4+ cells in the colon was significantly higher in Kyn-treated mice (*P* < 0.05) than in PBS-treated mice (Figure 5C, D). We next analyzed the mRNA expression levels of IL-10 and TGF-β. The levels of IL-10 mRNA in Kyn-treated mice (*P* < 0.05) were significantly upregulated compared to those in PBS-treated mice, whereas there was no significant change in the levels of TGF-β mRNA (Figure 5E). Similarly, the ratio of TGF-β+/Foxp3+ cells or IL-10+/ Foxp3+ cells in the ILF were significantly higher in Kyn-treated KMO−/− mice than in PBS-treated KMO+/+ mice (data not shown). These results suggest that the administration of Kyn as well as the inhibition of KMO reverse the exacerbation of TNBS-induced colitis via the induction or accumulation of anti-inflammatory cytokine producing Foxp3+ Treg cells.

**DISCUSSION**

In this study, the role of KMO in immune regulation was examined in *KMO* gene deficient mice suffering from TNBS-induced colitis. We demonstrated that the expression of TGF-β and IL-10 in the colon of these colitic mice was upregulated by KMO inhibition and Kyn administration, resulting in increased recruitment of Treg cells into the inflammatory site, where they suppress the progression of colitis.

KMO plays a major role in physiological and pathological events involving KP[20]. KMO activity is high in MPs, especially macrophages[21] and its expression is dependent on IFN-γ signaling[22]. Our results showed that the number of KMO+ cells, which are composed of F4/80+ and CD11c+ MPs, and mRNA expression level of KMO were significantly upregulated in the colon of TNBS-treated KMO+/+mice compared to vehicle mice. Interestingly, the absence or inhibition of KMO caused reduced inflammation and mucosal damage in the colon, suggesting that KMO+ MPs play a pivotal role in initiating inflammation in this model. In this context, various functions of KMO in immune regulation have been reported[23-31]. For example, the absence of KMO is associated with reduction of mortality in acute viral myocarditis[23] and prevention of multiple organ failure in acute pancreatitis[29]. Therefore, KMO+ MPs may be involved in the induction and progression of various inflammatory disorders.

Several studies have shown that the downstream metabolites of Trp possess immunomodulatory functions. Kyn, the first Trp metabolite, is known to act as an endogenous ligand for the aryl hydrocarbon receptor (AHR) that induces the generation of Treg cells through the expression of Foxp3[32,33]. Indeed, in the CpG-activated plasmacytoid dendritic cell-T cell co-culture system, the addition of 1-methyltryptophan, a representative inhibitor of IDO, significantly reduces the generation of Treg cells, whereas the addition of Kyn induces Treg generation even in the absence of endogenous IDO[25,34]. In line with these findings, the number of Treg cells in the colon is significantly increased in colitic KMO−/− mice, which have an elevated level of Kyn. Furthermore, the administration of Kyn to TNBS-treated KMO+/+ mice increased the number of Treg cells in the colon and reduced the pathology of colitis. Thus, the number of Treg cells in inflamed colon may be regulated by Kyn levels in the tissue. We also found that the level of 3-HK remained low in colitic KMO−/− mice and the administration of 3-HK to KMO−/− mice exacerbated colitis. These results suggest that KMO+ MPs might be a key player in the induction of colitis through their production of 3-HK.

Treg cells suppress Th1- and Th17-responses in colitis[35], and the removal of Treg cells worsens acute intestinal inflammation[10]. The suppressive effects of Treg cells on colitis are mediated by their production of IL-10 and TGF-β[36-38], suggesting that the regulation of Treg cells can aid in the treatment of IBD[39]. Indeed, in our study, TNBS-treated KMO−/− mice showed significantly increased frequency of IL-10- and TGF-β-producing Treg cells. However, the administration of Kyn in TNBS-treated KMO+/+ mice significantly increased the levels of IL-10, but not those of TGF-β in the colon. In addition, although the frequency of TGF-β- or IL-10-producing Foxp3+ cells was significantly higher in the ILF of TNBS-treated KMO−/− mice and Kyn-treated KMO+/+ mice than in TNBS-treated KMO+/+ mice, the frequency in the LP and MLN was unaffected, raising the question of how the Treg cells are generated in the ILF during colitis. In this regard, CD103+ DCs have been shown to induce the differentiation from naive T cells into Treg cells in the MLN and possibly the ILF in a TGF-β- and retinoic acid-dependent manner, and the Treg cells then migrate into the LP[40,41]. We found that the frequency of CD103+DCs in the MLN of colitic KMO−/− mice was higher than that in colitic KMO+/+ mice. Importantly, intestinal CD103+DCs that express IDO selectively induce Treg cells through their production of Kyn, thereby preventing colitis[42]. These findings suggest that the total number of Treg cells in the LP derived from the MLN and the ILF may be dependent on Kyn-producing CD103+DCs. Besides MLN-generated Treg cells, thymus-generated natural Treg cells have also been shown to contribute to the suppression of chronic colitis in a T-cell transfer model[43]. During colitis, the ILF and their related lymphoid-like structures are developed by the recruitment of various immune cells[44], including possibly Treg cells. Therefore, the generation of Treg cells in the ILF may be due to their recruitment from the MLN and the thymus.

In conclusion, we showed that the inhibition of KMO in the colon leads to increased levels of colonic Kyn, thereby suppressing colitis through Treg cell induction. Given that the administration of Kyn or inhibition of KMO are essential for Treg cell induction, our findings may contribute to the development of new therapeutic applications targeting Treg cells.

**REFERENCES**

1 **Strober W**, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *J Clin Invest* 2007; **117**: 514-521 [PMID: 17332878 DOI: 10.1172/jci30587]

2 **Xavier RJ**, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; **448**: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]

3 **Antignano F**, Burrows K, Hughes MR, Han JM, Kron KJ, Penrod NM, Oudhoff MJ, Wang SK, Min PH, Gold MJ, Chenery AL, Braam MJ, Fung TC, Rossi FM, McNagny KM, Arrowsmith CH, Lupien M, Levings MK, Zaph C. Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation. *J Clin Invest* 2014; **124**: 1945-1955 [PMID: 24667637 DOI: 10.1172/JCI69592]

4 **Maynard CL**, Weaver CT. Intestinal effector T cells in health and disease. *Immunity* 2009; **31**: 389-400 [PMID: 19766082 DOI: 10.1016/j.immuni.2009.08.012]

5 **Bouma G**, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol* 2003; **3**: 521-533 [PMID: 12876555 DOI: 10.1038/nri1132]

6 **Nakamura K**, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. *J Immunol* 2004; **172**: 834-842 [PMID: 14707053 DOI: 10.4049/jimmunol.172.2.834]

7 **Asseman C**, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *J Exp Med* 1999; **190**: 995-1004 [PMID: 10510089 DOI: 10.1084/jem.190.7.995]

8 **Read S**, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. *J Exp Med* 2000; **192**: 295-302 [PMID: 10899916 DOI: 10.1084/jem.192.2.295]

9 **Xu D**, Liu H, Komai-Koma M, Campbell C, McSharry C, Alexander J, Liew FY. CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. *J Immunol* 2003; **170**: 394-399 [PMID: 12496424 DOI: 10.4049/jimmunol.170.1.394]

10 **Boehm F**, Martin M, Kesselring R, Schiechl G, Geissler EK, Schlitt HJ, Fichtner-Feigl S. Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. *BMC Gastroenterol* 2012; **12**: 97 [PMID: 22849659 DOI: 10.1186/1471-230x-12-97]

11 **Mottet C**, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. *J Immunol* 2003; **170**: 3939-3943 [PMID: 12682220 DOI: 10.4049/jimmunol.170.8.3939]

12 **Fouser LA**, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. *Immunol Rev* 2008; **226**: 87-102 [PMID: 19161418 DOI: 10.1111/j.1600-065X.2008.00712.x]

13 **Izcue A**, Powrie F. Special regulatory T-cell review: Regulatory T cells and the intestinal tract--patrolling the frontier. *Immunology* 2008; **123**: 6-10 [PMID: 18154611 DOI: 10.1111/j.1365-2567.2007.02778.x]

14 **Izcue A**, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. *Annu Rev Immunol* 2009; **27**: 313-338 [PMID: 19302043 DOI: 10.1146/annurev.immunol.021908.132657]

15 **Izcue A**, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. *Immunol Rev* 2006; **212**: 256-271 [PMID: 16903919 DOI: 10.1111/j.0105-2896.2006.00423.x]

16 **Takamatsu M**, Hirata A, Ohtaki H, Hoshi M, Hatano Y, Tomita H, Kuno T, Saito K, Hara A. IDO1 plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. *J Immunol* 2013; **191**: 3057-3064 [PMID: 23956437 DOI: 10.4049/jimmunol.1203306]

17 **Munn DH**, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J Exp Med* 1999; **189**: 1363-1372 [PMID: 10224276 DOI: 10.1084/jem.189.9.1363]

18 **Fallarino F**, Grohmann U, Vacca C, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by kynurenines. *Adv Exp Med Biol* 2003; **527**: 183-190 [PMID: 15206731 DOI: 10.1007/978-1-4615-0135-0\_21]

19 **Von Bubnoff D**, Scheler M, Wilms H, Fimmers R, Bieber T. Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli. *J Immunol* 2011; **186**: 6701-6709 [PMID: 21543643 DOI: 10.4049/jimmunol.1003151]

20 **Kolodziej LR**, Paleolog EM, Williams RO. Kynurenine metabolism in health and disease. *Amino Acids* 2011; **41**: 1173-1183 [PMID: 20972599 DOI: 10.1007/s00726-010-0787-9]

21 **DE CASTRO FT**, BROWN RR, PRICE JM. The intermediary metabolism of tryptophan by cat and rat tissue preparations. *J Biol Chem* 1957; **228**: 777-784 [PMID: 13475359]

22 **Mándi Y**, Vécsei L. The kynurenine system and immunoregulation. *J Neural Transm (Vienna)* 2012; **119**: 197-209 [PMID: 21744051 DOI: 10.1007/s00702-011-0681-y]

23 **Kubo H**, Hoshi M, Mouri A, Tashita C, Yamamoto Y, Nabeshima T, Saito K. Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice. *Immunol Lett* 2017; **181**: 94-100 [PMID: 27889626 DOI: 10.1016/j.imlet.2016.11.012]

24 **Wang Y**, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. *Nat Med* 2010; **16**: 279-285 [PMID: 20190767 DOI: 10.1038/nm.2092]

25 **Chen W**, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. *J Immunol* 2008; **181**: 5396-5404 [PMID: 18832696 DOI: 10.4049/jimmunol.181.8.5396]

26 **Wirtz S**, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. *Nat Protoc* 2007; **2**: 541-546 [PMID: 17406617 DOI: 10.1038/nprot.2007.41]

27 **Saito K**, Quearry BJ, Saito M, Nowak TS Jr, Markey SP, Heyes MP. Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia. *Arch Biochem Biophys* 1993; **307**: 104-109 [PMID: 8239646 DOI: 10.1006/abbi.1993.1567]

28 **Hoshi M**, Matsumoto K, Ito H, Ohtaki H, Arioka Y, Osawa Y, Yamamoto Y, Matsunami H, Hara A, Seishima M, Saito K. L-tryptophan-kynurenine pathway metabolites regulate type I IFNs of acute viral myocarditis in mice. *J Immunol* 2012; **188**: 3980-3987 [PMID: 22422885 DOI: 10.4049/jimmunol.1100997]

29 **Mole DJ**, Webster SP, Uings I, Zheng X, Binnie M, Wilson K, Hutchinson JP, Mirguet O, Walker A, Beaufils B, Ancellin N, Trottet L, Bénéton V, Mowat CG, Wilkinson M, Rowland P, Haslam C, McBride A, Homer NZ, Baily JE, Sharp MG, Garden OJ, Hughes J, Howie SE, Holmes DS, Liddle J, Iredale JP. Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. *Nat Med* 2016; **22**: 202-209 [PMID: 26752518 DOI: 10.1038/nm.4020]

30 **Cozzi A**, Carpenedo R, Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. *J Cereb Blood Flow Metab* 1999; **19**: 771-777 [PMID: 10413032 DOI: 10.1097/00004647-199907000-00007]

31 **Stephens GL**, Wang Q, Swerdlow B, Bhat G, Kolbeck R, Fung M. Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands. *Eur J Immunol* 2013; **43**: 1727-1734 [PMID: 23568529 DOI: 10.1002/eji.201242779]

32 **Mezrich JD**, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. *J Immunol* 2010; **185**: 3190-3198 [PMID: 20720200 DOI: 10.4049/jimmunol.0903670]

33 **Quintana FJ**, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. *Nature* 2008; **453**: 65-71 [PMID: 18362915 DOI: 10.1038/nature06880]

34 **Fallarino F**, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. *J Immunol* 2006; **176**: 6752-6761 [PMID: 16709834 DOI: 10.4049/jimmunol.176.11.6752]

35 **Powrie F**, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. *Immunity* 1994; **1**: 553-562 [PMID: 7600284 DOI: 10.1016/1074-7613(94)90045-0]

36 **Sakaguchi S**. Regulatory T cells: key controllers of immunologic self-tolerance. *Cell* 2000; **101**: 455-458 [PMID: 10850488 DOI: 10.1016/s0092-8674(00)80856-9]

37 **Boden EK**, Snapper SB. Regulatory T cells in inflammatory bowel disease. *Curr Opin Gastroenterol* 2008; **24**: 733-741 [PMID: 19125486 DOI: 10.1097/mog.0b013e328311f26e]

38 **Barnes MJ**, Powrie F. Regulatory T cells reinforce intestinal homeostasis. *Immunity* 2009; **31**: 401-411 [PMID: 19766083 DOI: 10.1016/j.immuni.2009.08.011]

39 **Sumida Y**, Nakamura K, Kanayama K, Akiho H, Teshima T, Takayanagi R. Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. *Cytotherapy* 2008; **10**: 698-710 [PMID: 18985477 DOI: 10.1080/14653240802345812]

40 **Annacker O**, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, Agace WW, Parker CM, Powrie F. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. *J Exp Med* 2005; **202**: 1051-1061 [PMID: 16216886 DOI: 10.1084/jem.20040662]

41 **Coombes JL**, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. *J Exp Med* 2007; **204**: 1757-1764 [PMID: 17620361 DOI: 10.1084/jem.20070590]

42 **Nguyen NT**, Hanieh H, Nakahama T, Kishimoto T. The roles of aryl hydrocarbon receptor in immune responses. *Int Immunol* 2013; **25**: 335-343 [PMID: 23580432 DOI: 10.1093/intimm/dxt011]

43 **Makita S**, Kanai T, Nemoto Y, Totsuka T, Okamoto R, Tsuchiya K, Yamamoto M, Kiyono H, Watanabe M. Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation. *J Immunol* 2007; **178**: 4937-4946 [PMID: 17404275 DOI: 10.4049/jimmunol.178.8.4937]

44 **McNamee EN**, Rivera-Nieves J. Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur? *Front Immunol* 2016; **7**: 308 [PMID: 27579025 DOI: 10.3389/fimmu.2016.00308]

**Footnotes**

**Institutional review board statement:** This research was approved by the Ethics Committee of Fujita Health University.

**Institutional animal care and use committee statement:** This research was approved by Animal Experimental Ethical Inspection of Fujita Health University, NO. APU19040.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited Manuscript

**Peer-review started:** November 5, 2019

**First decision:** December 23, 2019

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yang MS, Sun XT **S-Editor:** Wang YQ **L-Editor: E-Editor:**

**Figure Legends**

****

**Figure 1 Increased number of F4/80+ KMO+ cells in the colon exacerbates TNBS-induced colitis.** Mice were treated with either TNBS or vehicle, and colons were collected three days after treatment. A: Histological scores determined based on a histological grading as described in Materials and Methods. B: Representative images of H&E-stained colons of the said mice. C, D: The KMO+ cells in the colons of the saidmice were counted using immunohistochemical staining for KMO. E: KMO mRNA expression in the colon was determined by quantitative PCR. F: The colons of TNBS-treated mice were stained for F4/80, CD19, CD11c, KMO, and DAPI (nuclei) using immunofluorescence staining. The negative controls for F4/80, CD19, CD11c, and KMO were not stained (Supplementary Figure 2 and 3). a*P* < 0.05 *vs* Vehicle group,b*P* < 0.01 *vs* Vehicle group, c*P* < 0.05 *vs* TNBS-treated KMO+/+ micegroup. KMO: Kynurenine 3-monooxygenase; TNBS: Trinitrobenzene sulfonic acid.



**Figure 2 TNBS treatment increased the levels of colon L-Kyn in absence of KMO.** KP metabolite levels in the colon of the indicated mice were measured using HPLC. The data are represented as mean ± SE from at least four independent experiments: a*P* < 0.05 *vs* Vehicle or TNBS-treated KMO+/+ mice group;b*P* < 0.01 *vs* Vehicle or TNBS-treated KMO+/+ mice group; c*P* < 0.05 *vs* KMO−/− Vehiclegroup; and d*P* < 0.01 *vs* Vehiclegroup. KMO: Kynurenine 3-monooxygenase; TNBS: Trinitrobenzene sulfonic acid.


テキスト が含まれている画像

自動的に生成された説明

**Figure 3 Regulation of KMO is involved in induction of Foxp3+ Treg cells.** A: Serial sections of the colons of the indicated mice were stained for Foxp3 and counterstained with hematoxylin. B–E: CD4+Foxp3+ cells and CD11c+CD103+ cells were analyzed using flow cytometry on colonic LP cells and MLN cells, respectively, from indicated mice, gated on 7-AAD-CD45.2+ cells. Representative flow cytometry plots and cumulative datagraphical summary are depicted. Data are representative of at least five independent experiments with similar results: a*P* < 0.05 *vs* TNBS-treatedKMO+/+mice group; c*P* < 0.05 *vs* KMO−/− Vehiclegroup. KMO: Kynurenine 3-monooxygenase; TNBS: Trinitrobenzene sulfonic acid.



**Figure 4 TNBS-treatment increased the levels of anti-inflammatory cytokines in the colon of KMO-deficient mice.** A: mRNA levels of TGF-β, IL-10, TNF-α, IFN-γ, and IL-17 in the colons of indicated mice were determined by quantitative PCR. B–C: Serial sections of the colons from vehicle or TNBS-treated KMO+/+ mice and TNBS-treated KMO+/+ or KMO−/− mice were stained for TGF-β, IL-10, Foxp3, and DAPI (nuclei). D: The ratio of TGF-β+ cells or IL-10+ cells to Foxp3+ Treg cells in ILF of TNBS-treated KMO+/+ mice or TNBS-treated KMO−/− mice. Negative controls for of TGF-β, IL-10 and Foxp3 were not stained (Supplementary Figure 3). The data are represented as mean ± SE from at least four independent experiments: a*P* < 0.05 *vs* TNBS-treated KMO+/+mice group;b*P* < 0.01 *vs* TNBS-treated KMO+/+mice group; d*P* < 0.01 *vs* KMO−/− Vehiclegroup. KMO: Kynurenine 3-monooxygenase; TNBS: Trinitrobenzene sulfonic acid; TGF-β: Transforming growth factor-β; IL-10: Interleukin-10; TNF-α: Tumor necrosis factor-α; IFN-γ: Interferon-γ; IL-17: Interleukin-17; Foxp3: Forkhead boxprotein P3.



**Figure 5 Administration of Kyn improved TNBS-induced colitis.** KMO+/+ and KMO−/− mice were treated with the indicated KP metabolites 12 h after TNBS injection, and the colons were collected on day 3. A: Histological inflammation scores for the colons of KP metabolite-treated mice or PBS-treated mice. B: Representative images of H&E-staining in the colon of indicated mice. C: The ratios of Foxp3+ Treg cells to total CD4+ T cells in the colons of mice. D: Serial sections of the colons of from indicated mice were stained for Foxp3 and counterstained with hematoxylin, allowing indication of Foxp3+ cells. E: The mRNA expression levels of TGF-β and IL-10 were determined by quantitative PCR. The data are represented as mean ± SE from at least four independent experiments: a*P* < 0.05 *vs* PBS-treated KMO−/−mice group;b*P* < 0.01 *vs* PBS-treated KMO+/+mice group. KMO: Kynurenine 3-monooxygenase; TNBS: Trinitrobenzene sulfonic acid; Kyn: Kynurenine; KA: Kynurenic acid; AA: Anthranilic acid; 3-HK: 3-hydroxykynurenine; 3-HAA: 3-hydroxyanthranilic acid; TGF-β: Transforming growth factor-β; IL-10: Interleukin-10; Foxp3: Forkhead boxprotein P3.